Quest Diagnostics Incorporated $DGX Stock: Yousif Capital Management LLC Raises Holdings

Key Points

• Yousif Capital Management increased its Quest Diagnostics stake by 67.3% in the third quarter, bringing its holdings to 25,173 shares valued at approximately $5.9 million. Institutional investors and hedge funds collectively own 88.06% of DGX.
• Quest exceeded third-quarter expectations with adjusted EPS of $3.00 and revenue of $3.10 billion, up 15.4% and 10% year over year, respectively. The company also raised its full-year 2026 revenue and adjusted-EPS guidance.
• A patient-data breach remains a significant risk, potentially exposing Quest to regulatory action, litigation, remediation costs and reputational damage, while insiders have sold more than $8.3 million of stock over the past three months.

Yousif Capital Management LLC lifted its stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 67.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,173 shares of the medical research company's stock after purchasing an additional 10,122 shares during the quarter. Yousif Capital Management LLC's holdings in Quest Diagnostics were worth $5,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Bank OZK acquired a new stake in shares of Quest Diagnostics during the 2nd quarter valued at $3,247,000. Assenagon Asset Management S.A. increased its stake in shares of Quest Diagnostics by 39.1% in the second quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company's stock worth $3,265,000 after acquiring an additional 4,334 shares during the last quarter. SGL Investment Advisors Inc. acquired a new position in shares of Quest Diagnostics in the second quarter worth $6,485,000. BlackRock Inc. purchased a new stake in shares of Quest Diagnostics during the second quarter worth $1,965,923,000. Finally, Simplicity Wealth LLC purchased a new stake in shares of Quest Diagnostics during the second quarter worth $4,702,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, SVP Michael Prevoznik sold 22,677 shares of the business's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the sale, the senior vice president owned 37,557 shares of the company's stock, valued at $9,130,482.27. The trade was a 37.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Delaney sold 1,600 shares of the business's stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares of the company's stock, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 34,277 shares of company stock worth $8,316,493 over the last three months. Corporate insiders own 0.88% of the company's stock.

Quest Diagnostics Stock Performance

Shares of DGX opened at $241.49 on Monday. The company's fifty day moving average is $237.67 and its 200-day moving average is $216.94. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $248.84. The firm has a market cap of $26.65 billion, a price-to-earnings ratio of 24.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.54. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.87 by $0.13. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The business had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the firm earned $2.60 EPS. Quest Diagnostics's revenue for the quarter was up 10.0% on a year-over-year basis. Equities analysts expect that Quest Diagnostics Incorporated will post 11.27 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th were issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.4%. The ex-dividend date was Tuesday, October 6th. Quest Diagnostics's dividend payout ratio (DPR) is 34.26%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DGX. Truist Financial lifted their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the company a "hold" rating in a research report on Monday, September 21st. JPMorgan Chase & Co. upped their target price on Quest Diagnostics from $220.00 to $250.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 28th. Argus set a $260.00 price target on Quest Diagnostics in a research note on Wednesday, July 29th. Jefferies Financial Group reaffirmed a "buy" rating and set a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Finally, Barclays lifted their price target on Quest Diagnostics from $250.00 to $260.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $244.27.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated NYSE: DGX is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.